

In re Esban et al.
Application No. 10/051,044

Page 2 of 5
5994.504-US

AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims.

LISTING OF CLAIMS

1-16 (cancelled)

17. (currently amended) A method of regulating increasing the expression of at least one gene of the CCN gene family in a cell, comprising the step of (a) contacting the said cell with activated Factor VII (FVIIa) a tissue factor agonist or a tissue factor antagonist, under conditions that result in a measurable increase change in said expression of the at least one gene and (b) detecting the increase in expression of the at least one gene.

18-21 (cancelled)

22. (currently amended) The method of claim 17, wherein said the at least one gene is selected from the group consisting of Cyr61, or connective tissue growth factor (CTGF), dopamine D2 receptor, EST Incyte PD 395116 and P2U nucleotide receptor.

23. (currently amended) The method of claim 22, wherein the at least one gene is Cyr61-gene.

24. (new) A method of treating burns in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating burns.

In re Esban et al.
Application No. 10/051,044

Page 3 of 5
5994.504-US

25. (new) A method of treating inflammation in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating inflammation.

26. (new) A method for inducing or enhancing the regeneration of vessel walls in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for inducing or enhancing the regeneration of vessel walls.

27. (new) The method of claim 17, wherein contacting the cell comprises delivering FVIIa to a patient comprising the cells.

28. (new) A method of treating a patient suffering from a pathological condition related to chemotaxis modulated by expression of at least one gene in the CCN gene family comprising delivering FVIIa to the patient under conditions suitable to increase expression of the at least one gene so as to treat the pathological condition.

29. (new) A method of treating a patient suffering from a pathological condition related to chemotaxis modulated by expression of at least one gene selected from the group consisting of dopamine D2 receptor, EST Incyte PD 395116, and P2U nucleotide receptor comprising delivering FVIIa to the patient under conditions suitable to treat the pathological condition.

30. (new) A method of increasing the expression of at least one gene selected from the group consisting of dopamine D2 receptor, EST Incyte PD 395116, and P2U nucleotide receptor, comprising (a) contacting the cell with FVIIa under conditions that result in a measurable increase in expression of the at least one gene and (b) detecting the increase in expression.